Loading menu...

Prostate Cancer (PCa) will affect most men if they live long enough and PCa is one of the leading causes of cancer deaths.

  		Each year over 200,000 men are newly diagnosed with PCa in North America.  CPC-100 is for asympto-matic 'watchfull waiting' PCa patients who fail prostate removal & hormone therapy, with no approved drug availble to them. 

Drugs for  therapy-resitant solid cancers & hypoxic conditions 

 Colby's mission is to develop & sell drugs for hypoxia & therapy-resistant tumors
Colby drugs resore therapy-sensitivity or normoxia

Pipeline

CPC-300

 

CPC-300 is a  multi-targeted, small molecule, signal transduction inhibitor drug.

In animal studies, CPC-300 has significant anti-cancer drug activity for therapy-resistant and hypoxic metastic solid tumors. CPC-300 is safe in animals and is in late pre-clinical development.